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Abstract 
Severe late toxicity following chemoradiotherapy in esophageal cancer, especially 
cardiac toxicity, is sometimes difficult to treat and is associated with mortality. However 
there is little published information with regard to patients with delayed pericardial 
effusion following chemoradiotherapy and its management. We herein report the case of 
a 63-year-old man with advanced synchronous esophageal and gastric cancers. This 
patient presented with pericardial effusion with cardiac tamponade after definitive 
chemoradiotherapy and was successfully treated with corticosteroid after 
pericardiocentesis. No instances of pericardial and pleural effusions were observed 
during the 2-year follow-up period until his death from cancer relapses. 
Introduction 
Chemoradiotherapy is a treatment of choice for patients with esophageal cancer. 
Reports indicate that it is comparable to surgery in terms of therapeutic outcome [1–3]. 
As the survival rate after chemoradiotherapy increases, management of the late adverse  
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effects of radiation becomes increasingly important [4–6]. Since patients with esophageal 
cancer receive a wide range of irradiation to the mediastinum and heart, they may 
develop postirradiation complications such as cardiac and pulmonary toxicities that have 
been reported in Hodgkin’s disease [7]. Severe late toxicity, especially cardiac toxicity, is 
sometimes difficult to treat and associated with mortality. However there is little 
published information with regard to patients with delayed pericardial effusion following 
chemoradiotherapy in esophageal cancer and its management. Here, we report a patient 
with advanced synchronous esophagus and gastric cardia cancers who presented with 
severe pericardial effusion as late toxicity. He was successfully treated with corticosteroid 
therapy following pericardial drainage. 
Case Report 
A 63-year-old man initially presented with dysphagia. He had a past history of surgery and 
radiotherapy for meningioma. Hematological tests revealed the levels of all tumor markers, namely 
squamous cell carcinoma antigen, carcinoembryonic antigen, and carbohydrate 19-9, to be in the 
normal range. The patient was diagnosed to have synchronous esophageal ulcerative tumor in the 
middle thoracic esophagus (fig. 1a) directly invading the thoracic aorta, accompanied by a gastric 
ulcerative tumor in the cardia (fig. 1b), concomitant with metastasis to the paraesophageal and 
abdominal lymph nodes. An endoscopic forceps biopsy specimen revealed moderately differentiated 
squamous cell carcinoma in the esophagus and well-differentiated adenocarcinoma in the stomach 
under microscopic examination. The patient was subsequently diagnosed with stage III (T4N1M0) 
esophageal carcinoma and stage III (T3N1M0) gastric carcinoma according to the TNM classification of 
the International Union against Cancer. He was treated with definitive chemoradiotherapy using a daily 
low dose of nedaplatin (CDGP) (10 mg/day) and a continuous infusion of 5-FU (500 mg/day) for 
20 days. Fractionated radiotherapy was performed since initiating chemotherapy and a total dose of 
66 Gy was delivered at the rate of 2 Gy per fraction. Initially, both tumors could be encompassed in a 
single radiation field that included the celiac nodes (fig. 2). The field was changed to avoid spinal cord 
irradiation following a dose of 40 Gy, and only thoracic macroscopic lesions were irradiated with a 
margin of at least 1 cm. An additional two cycles of maintenance chemotherapy were performed for 
5 days following chemoradiotherapy with CDGP (20 mg/day) and 5-FU (750 mg/day). Both tumors 
showed a clinically complete response (fig. 1c, d).  
However, 14 months after the chemoradiotherapy, the patient was readmitted to our hospital 
presenting with dyspnea and chest pain. His blood pressure fell to 92/68 mm Hg accompanied by a 
pulse rate of 116 bpm. A paradoxical pulse was observed. Chest radiograph indicated an enlarged 
cardiac silhouette with a left pleural effusion (fig. 3a). Computed tomography (CT) scan revealed 
pericardial effusion and a small amount of bilateral pleural effusion (fig. 4a). Echocardiography 
indicated an enlarged pericardium and collapsed ventricles with a left ventricular ejection fraction of 
63%. According to these findings pericardial and pleural effusions with cardiac tamponade were 
diagnosed. Pericardiocentesis and pericardial drainage were then performed. Pericardial fluid analysis 
showed a specific gravity of 1.033, protein 4.8 g/dl, and LDH 336 IU/l. Cultures and cytologic 
examinations of fluid specimens were repeatedly negative for bacteria and cancer cells. Pericardial 
drainage was performed for 5 days. However, the pericardial and left pleural effusions increased again. 
Pleural fluid composition was similar to that of pericardial fluid and its cytology was negative for cancer 
cells. Therapy with 40 mg prednisolone daily was started 30 days after pericardiocentesis. Immediately 
after adding steroid, the patient’s condition improved dramatically and a chest radiograph showed a 
decrease in cardiomegaly as well as pleural effusion (fig. 3b). Steroid was gradually reduced every 
2 weeks since then.  
As local recurrence of both the esophageal and the gastric tumors was revealed by endoscopy 
7 months after the treatment for pericardial and pleural effusion, chemotherapy using S-1 was 
performed. During a follow-up period of 2 years, no increases in the cardiothoracic ratio were observed 
on chest radiography (fig. 3c) and CT (fig. 4b). The patient survived until May 2008, after which he died 
from esophagorespiratory fistula and tumor bleeding.  
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Discussion 
We present a case of cardiac tamponade with pericardial effusion following 
chemoradiotherapy for advanced synchronous middle esophageal and cardial cancers, 
and successful treatment with corticosteroid therapy combined with pericardiocentesis. 
When pleural and pericardial effusions occur following chemoradiotherapy for 
esophageal or cardial cancer, the possibility of treatment-related complications must be 
considered by the physicians. Few clinical reports discussing late cardiac toxicity 
management following chemoradiotherapy in esophageal cancer therapy exist till date. 
The present case suggests the feasibility of steroid therapy as an alternative treatment for 
refractory pericardial effusion following chemoradiotherapy. 
Delayed complications following mediastinal radiotherapy or chemoradiotherapy 
include pericarditis, myocardial fibrosis, coronary artery disease, valvular abnormalities, 
conduction disturbances, and pulmonary fibrosis [8, 9]. Benign pericardial effusion 
following radiation therapy for esophageal or cardial cancer is considered a relatively rare 
event and accurate incidence data were not obtained until recently. A recent retrospective 
study revealed pericardial effusion to be the commonest cardiac toxicity in esophageal 
cancer patients with a crude incidence of 27.7% (28 of 101 patients) and median time at 
onset was 5.3 months (range 1.0–16.7 months) following chemoradiotherapy. In this 
study the actual incidence at 18 months was 48% (95% confidence interval 34–63) [10]. 
Treatment of pericardial effusion is not necessary in asymptomatic patients, whereas 
Ishikura et al. reported severe pericarditis (grade ≥3) in 10% (8 of 78 patients) and a few 
patients died as a result of heart failure despite pericardiocentesis or pericardial window 
placement [4]. 
It may be necessary to determine whether the effusion is associated with cancer 
relapses on observing such an effusion for the first time. In our case, repeated cytologic 
examinations of fluid specimens gave negative results for cancer relapse. External 
irradiation with a total dose of 66 Gy, delivered at the rate of 2 Gy per fraction, was 
performed in this case. It is known that a total dose greater than 35–40 Gy, daily 
fractionation in excess of 2 Gy, and volume of heart irradiated have been associated with 
an increased incidence of effusion [8]. As both lower esophageal cancer and cardial cancer 
were irradiated in our case, the field of irradiation involved a certain portion of the heart. 
It was suggested that the increased radiation volume and dose induced severe pericarditis. 
Daily low dose of CDGP and continuous infusion of 5-FU were given with radiation 
therapy in our case. Some chemotherapeutic agents have cardiotoxic effects. Doxorubicin 
is a well-known cardiotoxin that mainly affects the myocardium [11]. 5-FU also has a 
cardiotoxic effect [12] and is commonly used to treat esophageal cancer. However, it is 
not known whether it interacts with radiation to potentiate cardiotoxicity. In our recent 
clinical study, daily low dose of CDGP and 5-FU together with radiation for esophageal 
cancer did not seem to increase late cardiac toxicity [13]. To date, no other clinical factors 
have been found to influence the risk of pericardial effusion significantly following 
chemoradiotherapy for esophageal cancer, and high-dose radiation to the pericardium is 
the only significant risk associated with pericardial effusion [10, 14]. 
There is little published information with regard to delayed pericardial effusion 
management following chemoradiotherapy. Once delayed radiation cardiopulmonary 
toxicity occurs, there is no specific treatment other than steroids, diuretics, vasodilators, 
pericardiocentesis, pleurocentesis, pericardial window placement, and so on. There are 
only two clinical case reports in which radiation-induced pericardial effusions were 
successfully treated by steroid therapy: one was a case of breast cancer [15] and the other a  
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case of Hodgkin’s disease [16]. The pathology of radiation-induced heart disease is well 
characterized in an experimental rabbit model. Myocardial and pericardial fibroses, which 
appear to result from microcirculatory insufficiency and subsequent ischemia, dominate 
the late stage of radiation-induced heart disease [17, 18]. In this experimental model, early 
administration of methylprednisolone or ibuprofen decreases the incidence of pericardial 
effusion, reduces myocardial fibrosis, and improves survival [19]. Another clinical report 
indicated that rapid withdrawal of high-dose corticosteroids may activate subclinical 
radiation injury in the lungs and heart in Hodgkin’s disease [20]. Therefore, steroid 
treatment is a candidate for promising means of improving radiation-induced pericardial 
effusion. 
Pericardial effusion following chemoradiotherapy may sometimes be self-limited and 
asymptomatic, but is also sometimes difficult to treat and associated with mortality. 
Further clinical experience is necessary to establish the initiation of steroid therapy in 
treating pericardial effusion following chemoradiotherapy in the clinical setting. It is also 
important to determine the optimal dose of radiation, because the higher radiation dose 
did not increase survival or local/regional control and the dose of 50.4 Gy was 
recommended for patients treated with concurrent 5-FU and cisplatin chemotherapy 
according to the INT 0123 trial [21, 22]. Possible future treatments also include the use of 
new chemotherapeutic agents with both systemic and radiosensitizing activity so as to 
reduce toxicity. 
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Fig. 1. Endoscopic findings in esophageal and gastric cancers. a An esophageal lesion was 
demonstrated endoscopically as an ulcerative tumor in the middle thoracic esophagus. This was 
pathologically diagnosed as a moderately differentiated squamous cell carcinoma. b A gastric lesion 
was demonstrated as an ulcerative tumor in the cardia. It was pathologically diagnosed as a 
well-differentiated adenocarcinoma. Complete response was observed for the esophageal (c) and 
gastric cancers (d) 12 months following chemoradiotherapy, and was confirmed by endoscopic biopsy. 
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Fig. 2. Initial radiation field described as planning target volume. Initially, both esophageal and cardial 
cancers could be encompassed in a single radiation field. 
 
 
 
Fig. 3. Chest radiographies of the pericardial and pleural effusions. a The pretreatment chest 
radiograph indicated an enlarged cardiac silhouette with a left pleural effusion 14 months after initiating 
chemoradiotherapy. b A chest radiograph after 8 days of corticosteroid administration (40 mg/day) 
indicated improvement in the enlarged cardiac silhouette and pleural effusion. c No recurrence of the 
effusions was observed 9 months after initiating steroid therapy. 
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Fig. 4. CT scan findings of the pericardial and pleural effusions. a The pretreatment CT scan 
revealed pericardial effusion and a small amount of bilateral pleural effusion 14 months after 
chemoradiotherapy. b The posttreatment CT scan indicated no recurrence of either pericardial or 
bilateral pleural effusions 12 months after initiating steroid therapy. 
 
  
Case Rep Gastroenterol 2010;4:229–237 
DOI: 10.1159/000318751 
Published online: July 24, 2010  © 2010 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
236
References 
1 Kleinberg L, Forastiere AA: Chemoradiation in the management of esophageal 
cancer. J Clin Oncol 2007;25:4110–4117. 
2 Kleinberg L, Gibson MK, Forastiere AA: Chemoradiotherapy for localized 
esophageal cancer: regimen selection and molecular mechanisms of 
radiosensitization. Nat Clin Pract Oncol 2007;4:282–294. 
3 Ohtsu A: Chemoradiotherapy for esophageal cancer: current status and 
perspectives. Int J Clin Oncol 2004;9:444–450. 
4 Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, Muto M, Ogino T, 
Yoshida S: Long-term toxicity after definitive chemoradiotherapy for squamous 
cell carcinoma of the thoracic esophagus. J Clin Oncol 2003;21:2697–2702. 
5 Kumekawa Y, Kaneko K, Ito H, et al: Late toxicity in complete response cases 
after definitive chemoradiotherapy for esophageal squamous cell carcinoma. 
J Gastroenterol 2006;41:425–432. 
6 Morota M, Gomi K, Kozuka T, Chin K, Matsuura M, Oguchi M, Ito H, Yamashita 
T: Late toxicity after definitive concurrent chemoradiotherapy for thoracic 
esophageal carcinoma. Int J Radiat Oncol Biol Phys 2009;75:122–128. 
7 Cosset JM, Henry-Amar M, Pellae-Cosset B, Carde P, Girinski T, Tubiana M, 
Hayat M: Pericarditis and myocardial infarctions after Hodgkin’s disease therapy. 
Int J Radiat Oncol Biol Phys 1991;21:447–449. 
8 Gaya AM, Ashford RF: Cardiac complications of radiation therapy. Clin Oncol 
(R Coll Radiol) 2005;17:153–159. 
9 Marks LB, Yu X, Vujaskovic Z, Small W Jr, Folz R, Anscher MS: 
Radiation-induced lung injury. Semin Radiat Oncol 2003;13:333–345. 
10 Wei X, Liu HH, Tucker SL, Wang S, Mohan R, Cox JD, Komaki R, Liao Z: Risk 
factors for pericardial effusion in inoperable esophageal cancer patients treated 
with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys 
2008;70:707–714. 
11 de Graaf H, Dolsma WV, Willemse PH, van der Graaf WT, Sleijfer DT, de Vries 
EG, Mulder NH: Cardiotoxicity from intensive chemotherapy combined with 
radiotherapy in breast cancer. Br J Cancer 1997;76:943–945. 
12 Becker K, Erckenbrecht JF, Haussinger D, Frieling T: Cardiotoxicity of the 
antiproliferative compound fluorouracil. Drugs 1999;57:475–484. 
13 Osawa S, Furuta T, Sugimoto K, et al: Prospective study of daily low-dose 
nedaplatin and continuous 5-fluorouracil infusion combined with radiation for 
the treatment of esophageal squamous cell carcinoma. BMC Cancer 2009;9:408. 
14 Sasamoto R, Tsuchida E, Sugita T, Matsumoto Y, Abe E, Sasai K: Risk factors for 
enlargement of cardiac silhouette on chest radiography after radiotherapy for 
esophageal cancer. Radiat Med 2006;24:431–437. 
15 Biran S: Corticosteroids in radiation-induced pericarditis. Chest 1978;74:96–98. 
16 Keelan MH Jr, Rudders RA: Successful treatment of radiation pericarditis with 
corticosteroids. Arch Intern Med 1974;134:145–147. 
17 Stewart JR, Fajardo LF: Radiation-induced heart disease: an update. 
Prog Cardiovasc Dis 1984;27:173–194. 
18 Fajardo LF, Stewart JR: Pathogenesis of radiation-induced myocardial fibrosis. 
Lab Invest 1973;29:244–257. 
19 Reeves WC, Cunningham D, Schwiter EJ, Abt A, Skarlatos S, Wood MA, 
Whitesell L: Myocardial hydroxyproline reduced by early administration of 
methylprednisolone or ibuprofen to rabbits with radiation-induced heart disease. 
Circulation 1982;65:924–927. 
20 Castellino RA, Glatstein E, Turbow MM, Rosenberg S, Kaplan HS: Latent 
radiation injury of lungs or heart activated by steroid withdrawal. Ann Intern 
Med 1974;80:593–599. 
21 Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, 
Okawara G, Rosenthal SA, Kelsen DP: INT 0123 (Radiation Therapy Oncology 
Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: 
high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167–
1174. 
22 Hong TS, Crowley EM, Killoran J, Mamon HJ: Considerations in treatment 
planning for esophageal cancer. Semin Radiat Oncol 2007;17:53–61.  
Case Rep Gastroenterol 2010;4:229–237 
DOI: 10.1159/000318751 
Published online: July 24, 2010  © 2010 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
237
 
 
S.O. wrote the manuscript. T.Y., K.S. and M.I. contributed to the paper design and coordination. T.S. 
contributed to the assessment of cardiology. T.K. contributed to the planning of irradiation. T.T., Y.H. 
and Y.T. were involved in chemoradiotherapy, treatment for delayed complications, and follow-up. All 
authors have read and approved the final manuscript. 